Table 2.
Patient number, n | 214 |
Age, years | 60 (37–70) |
Gender, n (%) | |
Male | 129 (60.3) |
Female | 85 (39.7) |
Heavy chain type, n (%) | |
IgG | 136 (63.6) |
IgA | 30 (14.0) |
Other (IgM, IgD, and IgE) | 4 (1.9) |
None | 44 (20.6) |
Light chain type, n (%) | |
κ | 146 (68.2) |
λ | 68 (31.8) |
β2-microglobulin (mg/l) | 3.4 (1.0–17.4) |
Albumin (g/l) | 37 (20.0–56.0) |
ISS, n (%) | |
I | 80 (37.4) |
II | 81 (37.9) |
III | 53 (24.8) |
Cytogenetic risk groupa, n (%) | |
Standard risk | 155 (79.5) |
High risk | 40 (20.5) |
Missing | 19 |
Cytogenetic risk groupb, n (%) | |
Standard risk | 149 (76.4) |
High risk | 46 (23.6) |
Missing | 19 |
Immonophenotypic prognostic markers, n (%) | |
CD27-positive | 196 (96.5) |
CD27-negative | 7 (3.4) |
Missing | 11 |
CD81-positive | 140 (69.3) |
CD81-negative | 62 (30.7) |
Missing | 12 |
Unless indicated otherwise, data are presented as medians (ranges)
ISS International Staging System
aCytogenetic high-risk group: presence of del17p and/or t(4;14) or a gain at 1q of >3 copies
bCytogenetic high-risk group: presence of del17p and/or t(4;14) or t(14;16)